Radiology Partners

radpartners.com

Radiology Partners is a multi-state hospital-based practice, serving in excess of 100 locations, with the infrastructure and capital to scale further. We offer diagnostic and interventional radiology services, with on-site and remote reads by local radiologists. Radiology Partners is the fastest-growing radiology practice in the U.S., with an exceptional client relationship track record that spans 40 years.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LOGICBIO ROCKED BY FDA CLINICAL HOLD ON GENOME EDITING TRIAL

FierceBiotech | February 11, 2020

news image

The FDA has placed a clinical hold on LogicBio Therapeutics’ planned genome editing trial. LogicBio wants to trial the therapy in methylmalonic acidemia (MMA) patients aged two years and up but has run into resistance at the FDA. Details of the nature of the regulatory resistance and how soon it is likely to be resolved are scarce. LogicBio provided scant information in its statement to disclose the FDA clinical hold. According to analysts at Jefferies who spoke to management at LogicBio, ...

Read More

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

news image

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More

INTRAVACC'S CANDIDATE RSV VACCINE DEMONSTRATES SAFETY IN PHASE I TRIAL

Intravacc | August 18, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...

Read More

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

PR.com | February 04, 2020

news image

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More
news image

LOGICBIO ROCKED BY FDA CLINICAL HOLD ON GENOME EDITING TRIAL

FierceBiotech | February 11, 2020

The FDA has placed a clinical hold on LogicBio Therapeutics’ planned genome editing trial. LogicBio wants to trial the therapy in methylmalonic acidemia (MMA) patients aged two years and up but has run into resistance at the FDA. Details of the nature of the regulatory resistance and how soon it is likely to be resolved are scarce. LogicBio provided scant information in its statement to disclose the FDA clinical hold. According to analysts at Jefferies who spoke to management at LogicBio, ...

Read More
news image

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More
news image

INTRAVACC'S CANDIDATE RSV VACCINE DEMONSTRATES SAFETY IN PHASE I TRIAL

Intravacc | August 18, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...

Read More
news image

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

PR.com | February 04, 2020

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us